NEW UPDATE: Completed trials may now upload and register supplementary documents (e.g. null results reports, populated pre-analysis plans, or post-trial results reports) in the Post Trial section under Reports, Papers, & Other Materials.
The Economics Consequences of Depression: Evidence from Goa
Initial registration date
January 26, 2019
January 28, 2019 2:36 AM EST
This section is unavailable to the public. Use the button below
to request access to this information.
Other Primary Investigator(s)
Massachusetts Institute of Technology
Additional Trial Information
The goal of this study is to estimate the effects of treating Major Depressive Disorder ("Depression") on economic behavior. The study follows up on two recently-completed randomized control trials of low-cost psychotherapy to treat depression in Goa, India, conducted by the NGO Sangath and led by Professor Vikram Patel. We will study the impact of the treatments (and the resulting reduced levels of depression) on beliefs, preferences and decision-making, and other economic outcomes.
This study follows up on two randomized controlled trials of low-cost psychotherapy run by the NGO Sangath in Goa, India: PREMIUM and SHARE.
Intervention Start Date
Intervention End Date
Primary Outcomes (end points)
Primary outcomes are the level of overconfidence, biases in beliefs updating, the decision on the main hiring opportunity, and risk, time, social preferences and susceptibility to defaults effects. This is described in more details in the document.
Primary Outcomes (explanation)
See the PDF.
Secondary Outcomes (end points)
Consumption, education and human capital investments, intimate partner violence, women's empowerment, mood, loneliness, sleep quality and locus of control, labor supply and earnings, the reservation wage measured in our experiment, and the performance at bracelets making.
Secondary Outcomes (explanation)
See the accompanying PDF.
Experimental Design Details
Randomization done by a computer.
Was the treatment clustered?
Sample size: planned number of clusters
Sample size: planned number of observations
Sample size (or number of clusters) by treatment arms
247 (PREMIUM EUC+HAP), 248 (PREMIUM EUC), 140 (SHARE EUC+THPP), 140 (SHARE EUC)
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
INSTITUTIONAL REVIEW BOARDS (IRBs)
IRB Approval Date
IRB Approval Number